Diffusion MRI tracks cortical microstructural changes during the early stages of Alzheimer’s disease.

1 March, 2024

Interactions between vascular burden and amyloid-β pathology on trajectories of tau accumulation.

Highly Accurate Blood Test for Alzheimer’s Disease Comparable or Superior to Clinical CSF Tests.

21 February, 2024

Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease.

17 February, 2024

Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study.

13 February, 2024

The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer’s Disease Pathology.

11 February, 2024

Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis.

Effects of certain pre-analytical factors on the performance of plasma phospho-tau217.

8 February, 2024

Combined Connectomics, MAPT Gene Expression, and Amyloid Deposition to Explain Regional Tau Deposition in Alzheimer Disease.

Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases.

7 February, 2024

Diffusion weighted magnetic resonance spectroscopy revealed neuronal specific microstructural alterations in Alzheimer’s disease.

1 February, 2024

Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer’s disease pathology.

7 January, 2024

The fluorescent ligand bTVBT2 reveals increased p-tau uptake by retinal microglia in Alzheimer’s disease patients and App^NL-F/NL-F mice.

2 January, 2024

Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies.

1 January, 2024

Harnessing cognitive trajectory clusterings to examine subclinical decline risk factors.

3 December, 2023

The molecular genetic landscape of human brain size variation.

28 November, 2023

Effects of Brain Pathologies on Spatiotemporal Gait Parameters in Patients with Mild Cognitive Impairment.

31 October, 2023

The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases.

27 October, 2023

DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease.

3 October, 2023

Microglial activation protects against accumulation of tau aggregates in nondemented individuals with underlying Alzheimer’s disease pathology.

11 September, 2023

Associations of CSF PDGFRβ With Aging, Blood-Brain Barrier Damage, Neuroinflammation, and Alzheimer Disease Pathologic Changes.

Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Higher plasma β-synuclein indicates early synaptic degeneration in Alzheimer’s disease.

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.

Plasma neurofilament light in behavioural variant frontotemporal dementia compared to mood and psychotic disorders.

Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.

Blood biomarkers for Alzheimer’s disease in clinical practice and trials.

11 August, 2023

CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer’s disease.

12 June, 2023

Age-related and amyloid-beta-independent tau deposition and its downstream effects.

Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the App^NL-F/NL-F knock-in mouse model of Alzheimer’s disease.

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease.

Associations Between CSF Markers of Inflammation, White Matter Lesions, and Cognitive Decline in Individuals Without Dementia.

Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.

Discriminative accuracy of the A/T/N scheme to identify cognitive impairment due to Alzheimer’s disease.

Robustness of CSF Aβ42/40 and Aβ42/P-tau181 measured using fully automated immunoassays to detect AD-related outcomes.

Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.

Tau-PET is superior to phospho-tau when predicting cognitive decline in symptomatic AD patients.

Novel insights regarding the measurement properties of the SCOPA-AUT.

[¹⁸F]RO948 tau positron emission tomography in genetic and sporadic frontotemporal dementia syndromes.

Antibody-free measurement of cerebrospinal fluid tau phosphorylation across the Alzheimer’s disease continuum.

The genetic regulation of protein expression in cerebrospinal fluid.

Cerebrospinal Fluid Biomarkers of Synaptic Dysfunction are Altered in Parkinson’s Disease and Related Disorders.

Performance of [¹⁸F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy.

Gray matter hypoperfusion is a late pathological event in the course of Alzheimer’s disease.

CSF ferritin in the clinicopathological progression of Alzheimer’s disease and associations with APOE and inflammation biomarkers.

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease.

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer’s disease.

Axonal degeneration and amyloid pathology predict cognitive decline beyond cortical atrophy.

Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease.

Confounding factors of Alzheimer’s disease plasma biomarkers and their impact on clinical performance.

Clinical performance and robustness evaluation of plasma amyloid-β_42/40prescreening.

Measures of cortical microstructure are linked to amyloid pathology in Alzheimer’s disease.

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease.

Phospho-tau with subthreshold tau-PET predicts increased tau accumulation rates in amyloid-positive individuals.

Anterior cingulate sulcation is associated with onset and survival in frontotemporal dementia.

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.

Spatial Navigation and Its Association With Biomarkers and Future Dementia in Memory Clinic Patients Without Dementia.

17 June, 2022

Earlier Alzheimer’s disease onset is associated with tau pathology in brain hub regions and facilitated tau spreading.

An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease.

Clinically Relevant Changes for Cognitive Outcomes in Preclinical and Prodromal Cognitive Stages: Implications for Clinical Alzheimer Trials.

Performance of αSynuclein RT-QuIC in relation to neuropathological staging of Lewy body disease.

Astrocytic function is associated with both amyloid-β and tau pathology in non-demented APOE ϵ4 carriers.

Test-retest variability of plasma biomarkers in Alzheimer’s disease and its effects on clinical prediction models.

β-Amyloid-Dependent and -Independent Genetic Pathways Regulating CSF Tau Biomarkers in Alzheimer Disease.

Diagnostic and prognostic performance to detect Alzheimer’s disease and clinical progression of a novel assay for plasma p-tau217.

Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer’s dementia in mild cognitive impairment patients.

Development of Apathy, Anxiety, and Depression in Cognitively Unimpaired Older Adults: Effects of Alzheimer’s Disease Pathology and Cognitive Decline.

Midsagittal corpus callosal thickness and cognitive impairment in Parkinson’s disease.

Subtypes of Alzheimer’s disease: questions, controversy, and meaning.

Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.

The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.

Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer’s disease and frontotemporal disorders in clinical settings.

Components of gait in people with and without mild cognitive impairment.

Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Blood-based biomarkers for Alzheimer’s disease.

Blood-based biomarkers for Alzheimer’s disease: towards clinical implementation.

Serum Neurofilament Light Chain as a Marker of Progression in Parkinson’s Disease: Long-Term Observation and Implications of Clinical Subtypes.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Decreased pain sensitivity and alterations of cerebrospinal fluid and plasma inflammatory mediators after total hip arthroplasty in patients with disabling osteoarthritis.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

Prenatal Gyrification Pattern Affects Age at Onset in Frontotemporal Dementia.

Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition.

Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.

Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson’s disease.

30 June, 2021

Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

24 June, 2021

Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.

14 June, 2021

Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.

The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals.

Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: Results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group.

Connecting Cohorts to Diminish Alzheimer’s Disease (CONCORD-AD): A Report of an International Research Collaboration Network.

The global Alzheimer’s Association round robin study on plasma amyloid β methods.

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease.

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease.

Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.

Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer’s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study.

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum.

Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience.

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease.

Tau PET correlates with different Alzheimer’s disease-related features compared to CSF and plasma p-tau biomarkers.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging.

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau.

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.

A multicentre validation study of the diagnostic value of plasma neurofilament light.

Sex differences in off-target binding using tau positron emission tomography.

Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects.

The BIN1 rs744373 Alzheimer’s disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline.

A multicenter comparison of [¹⁸F]flortaucipir, [18F]RO948, and [¹⁸F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis.

Health utility in preclinical and prodromal Alzheimer’s disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.

Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau.

Four distinct trajectories of tau deposition identified in Alzheimer’s disease.

Cerebrospinal fluid N-224 tau helps discriminate Alzheimer’s disease from subjective cognitive decline and other dementias.

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia.

Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid,
tau, and cognition.

The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer’s
disease.

Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer’s
disease.

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for
synaptic biomarkers.

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future
conversion to Alzheimer dementia in patients with mild cognitive impairment.

A multisite analysis of the concordance between visual image interpretation and
quantitative analysis of [¹⁸F]flutemetamol amyloid PET images.

Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer’s
disease.

Biomarker testing in MCI patients-deciding who to test.

Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts.

Early stages of tau pathology and its associations with functional connectivity, atrophy and memory.

30 April, 2021

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

3 February, 2021

Pre-analytical protocol for measuring Alzheimer’s disease biomarkers in fresh CSF.

Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies.

Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease.

29 January, 2021

Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease.

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects.

Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.

Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

28 July, 2020

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

24 July, 2020

Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease

Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia

Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer’s disease

Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease.

14 June, 2020

Plasma Phospho-Tau Identifies Alzheimer’s Co-Pathology in Patients with Lewy Body Disease.

Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias.

Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer’s disease.

Plasma NT1 Tau is a Specific and Early Marker of Alzheimer’s Disease.

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease.

The impact of demographic, clinical, genetic, and imaging variables on tau PET status.

Acute phase markers in CSF reveal inflammatory changes in Alzheimer’s disease that intersect with pathology, APOE ε4, sex and age.

Image reconstruction methods affect software-aided assessment of pathologies of [¹⁸F]flutemetamol and [¹⁸F]FDG brain-PET examinations in patients with neurodegenerative diseases.

Validation of a spatial normalization method using a principal component derived adaptive template for [¹⁸F]florbetaben PET.

Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up.

The effects of tau, amyloid and white matter lesions on mobility, dual tasking and balance in older people.

Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease.

Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.

CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers.

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

The implications of different approaches to define AT(N) in Alzheimer disease.

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders.

Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.

Relationship between cortical iron and tau aggregation in Alzheimer’s disease.

Medial temporal lobe connectivity and its associations with cognition in early Alzheimer’s disease.

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease.

The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment.

Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding.

Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson’s disease.

[¹⁸F]Flortaucipir Distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case.

Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. 

Head-to-head comparison of tau positron emission tomography tracers  [¹⁸F]flortaucipir and [¹⁸F]RO948.

Apathy and anxiety are early markers of Alzheimer’s disease.

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease.

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume.

13 June, 2019

Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders.

Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from α-Synucleinopathies. 

Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity.

Predicting Clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays

Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer’s disease.

Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer’s disease. 

A quick test of cognitive speed can predict development of dementia in Parkinson’s disease. 

Autocatalytic amplification of Alzheimer-associated Aβ42 peptide aggregation in human cerebrospinal fluid.

Alzheimer’s Disease Neuroimaging Initiative. Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study.

Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease. 

Increased functional connectivity of thalamic subdivisions in patients with Parkinson’s disease.

β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. 

α-synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson’s disease patients.  

Determining clinically meaningful decline in preclinical Alzheimer disease.

Towards a unified protocol for handling of CSF before β-amyloid measurements. 

Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. 

Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study.

European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). 

Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related β-Amyloid Status. 

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease. 

Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. 

Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. 

Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. 

Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline.

Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease. 

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia. 

Accurate risk estimation of β-amyloid positivity to identify prodromal Alzheimer’s disease: Cross-validation study of practical algorithms. 

Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. 

Data-driven approaches for tau-PET imaging biomarkers in Alzheimer’s disease.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer’s disease.